DOCSLIB.ORG

223 © Springer International Publishing Switzerland 2017 A. Tosti Et Al. (Eds.), Onychomycosis, DOI 10.1007/978-3-319-44853-4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
223 © Springer International Publishing Switzerland 2017 A. Tosti Et Al. (Eds.), Onychomycosis, DOI 10.1007/978-3-319-44853-4 Index A naftifine hydrochloride, 209 Albaconazole, 208 nail abrasion, 210 Allylamines, 205 tavaborole topical solution, 209 Alternaria alternata, 88, 90 Apple cider vinegar (ACV), 216 Ambulation disorders Arthroconidium, 7 asymmetrical gait nail unit syndrome, 187 Aspergillus, 62 biomechanical problems, 187–188 A. niger, 88 Amphotericin B, 205 Asymmetrical gait nail unit syndrome, 187 Antifungal drugs Azoles, 205 allylamines, 205 amphotericin B, 205 azoles, 205 B echinocandins, 205 Black nail pigmentation, 97 5-fluorocytosine, 205 Black superficial onychomycosis, 90 griseofulvin, 205 naftifine, 205 pigmented onychomycosis, 98 C systemic Candida, 4–5 albaconazole, 208 causes, 73 fluconazole, 207 clinical features, 76–77 itraconazole, 208 C. parapsilosis, 75, 80, 91 miconazole, 208 culture, SDA, 106–107 posaconazole, 208 diagnosis pramiconazole, 208 biochemical tests, 79 ravuconazole, 210 clinical presentation, 77–78 terbinafine, 205, 208, 210 culture, 79, 80 voriconazole, 208 DNA sequencing-based tests, 80 topical laboratory tests, 79 ciclopirox hydro-lacquer, 209 microscopy, 78–79 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-­ nail examination, 78 methylphenol, 210 route of, 77 efinaconazole, 209 epidemiology, 74–76 iontophoresis, 210 PSO, 47–48, 52 laser nail ablation, 210 significant negative effects, 73–74 laser therapy, 210 Carbon dioxide (CO2) laser system, 195 luliconazole, 210 Cellulitis, 4, 22, 165–167 microporation, 210 Chlorazol black, 78, 105 © Springer International Publishing Switzerland 2017 223 A. Tosti et al. (eds.), Onychomycosis, DOI 10.1007/978-3-319-44853-4 224 Index Ciclopirox hydro-lacquer, 209 toenail debridement, 171 Classical superficial white onychomycosis, 37, topical ciclopirox nail lacquer, 172 38 Dimethyl sulfoxide (DMSO), 52 Contact dermatitis Distal lateral subungual onychomycosis (DLSO) clinical features, 148, 149 clinical features, 26–30 diagnosis, 155 complications, 22 epidemiology, 148 contact dermatitis, 148 Cycloheximide, 53, 67–68 dermoscopy, 133 diagnostic clues, 30–32 differential diagnosis, 142 D drug-induced onycholysis, 152–153 Deep superficial white onychomycosis, 37–39, epidemiology 64, 65 diabetes, 24 Dermoscopy fingernail, 25 black pigment aggregates, 138 prevalence, 23 black reverse triangle, 138 risk factors, 23–24 blurred appearance, 138 and tinea pedis, 24, 25 distal irregular termination, 135, 137 two feet-one hand syndrome, 25, 26 fungal melanonychia, 135, 137 fungal infection intermediate nail plate invasion, 64–65 patterns of, 5 jagged proximal edge, onycholytic area, progression of, 21, 22 135, 136 lichen planus, 144 longitudinal striae, 135, 136 nail psoriasis, 142–143 matte black pigmentation, 138 non-dermatophytic molds, 64–66 multicolored pigmentation, 138 onycholysis, thyroid disease, 151 nail pigmentations, 134 pachyonychia congenita, 149–151 pigmented onychomycosis, 92 physical symptoms, 22 PSO, 50 subungual tumors, 144–148 superficial transverse striation, 138 traumatic onycholysis, 148–149 SWO, 35, 36 yellow nail syndrome, 151–152 Diabetics DLSO. See Distal lateral subungual biomechanics, 170 onychomycosis (DLSO) distal subungual onychomycosis, 171 DNA extraction, 114–115 foot ulcer, 170 DNA sequencing-based tests, 80 long-standing hyperglycemia, 170 Drug-induced onycholysis mycotic toenail infections, 169, 170 clinical features, 152–153 with neuropathy, 170 diagnosis, 156 pedal ambulation, 170 epidemiology, 152 predisposing factors, 170 photo-onycholysis, 152–153 prevalence and risk factors, 169–170 taxanes, 153 shoe gear and systemic tetracyclines, 152 immunosuppression, 170 Drug longitudinal melanonychia, 95, 96 tinea pedis, 171 Dual wavelength 870/930 nm laser therapy, 195 treatment antifungal therapy, 171 concomitant tinea pedis, 171 E drug therapies, 171 Echinocandins, 205 efinaconazole, 173 Efinaconazole, 198–199, 209 insulin-dependent, 172 Endonyx onychomycosis (EO), 6 laser therapy, 173 clinical features, 58 nail debridement, 171–172 diagnosis, 58, 59 non-insulin-dependent, 172 epidemiology, 58 oral itraconazole therapy, 172 nail invasion pattern, 57 oral terbinafine, 172 Exostosis, 145–146 Index 225 F ABCDEF guidelines, 155 Fluconazole, 207 mimickers, 147–148 5-Fluorocytosine, 205 pigmented onychomycosis, 96–98 Fungal melanonychia. See Pigmented Methyl aminolevulinate (MAL), 68 onychomycosis Miconazole, 208 Fungal nail infections. See Onychomycosis Microporation, 210 Mimickers diagnostic clues, 155–156 G distal subungual (see Distal subungual Gene target, 116–117 onychomycosis) GMS. See Grocott methenamine silver (GMS) proximal subungual (see Proximal staining subungual onychomycosis) Granuloma, Candida, 77 white subungual (see White subungual Grocott methenamine silver (GMS) staining, onychomycosis) 53, 124 Mixed pattern onychomycosis (MPO), 6 Griseofulvin, 205 N H N-Acetylglucosamine (GlcNAc), 89 Hematoma Naftifine, 205, 209 mimickers, 149 Nail(s) pigmented onychomycosis, 94 abrasion, 210 Host defense, 89 pigmentation Hutchinson’s sign, 96–98, 147 dermatoscopy, 97 I drug longitudinal melanonychia, Iontophoresis, 210 95, 96 Itraconazole, 208 longitudinal melanonychia, 95 melanoma, 96–97 racial longitudinal melanonychia, K 93–94 KOH. See Potassium hydroxide (KOH) subungual nevus, 96 plate composition, 6 L DSLO, 27–28 Lacquer-based topical therapies, 198 electron microscopy, 124 Laser nail ablation, 210 EO, 58, 59 Laser therapy, 193–195 evaluation, 93 Laugier-Hunziker syndrome, 95 hematoma, 94 Lichen planus jagged/sharp edges, 166 clinical features, 144 longitudinal nail biopsy, 125, 126 epidemiology, 144 pigmented distal subungual Longitudinal melanonychia onychomycosis, 65–66 drug, 95 SWO, 36 endocrine, 95 TDO, 134 racial, 93, 94 psoriasis squamous cell carcinoma with, 147 clinical features, 142–143 Luliconazole, 210 epidemiology, 142 leukonychia, 143 splinter hemorrhages, 143 M subungual hyperkeratosis, 143 MAL. See Methyl aminolevulinate Nail bed lichen planus, 155 (MAL) Neodymium-doped yttrium aluminum garnet Maladie dermatophytique, 46 (Nd:YAG) laser, 194 Melanoma Neoscytalidium dimidiatum, 66, 87, 97 226 Index O flow cytometry, 128–129 Onycholysis fluorescence microscopy, 128 Candida, 77 foot ulceration, 167 drug-induced onycholysis, 152–153, 156 fungal culture, 113, 132 DSLO, 26, 27, 29 gangrene, diabetic patients, 167 proximal, 154 histopathology, 110 thyroid disease Candida onychomycosis, 125, 127 clinical features, 151 dermatophytes, 124 diagnosis, 156 diagnosis, 123 epidemiology, 151 hematoxylin and eosin stain, 124 toenail onychodystrophy, 185 histological examination, 125, 126 traumatic, 148–150, 156 nail biopsy, 124, 125 Onychomycosis nail clippings, fungal stains, 124 animal models, 8 PAS staining, 124, 125 antifungal drugs home remedies allylamines, 205 ACV, 216 amphotericin B, 205 bleach and tea tree oil, 216 azoles, 205 Listerine, 216 echinocandins, 205 oil of oregano, 216 5-fluorocytosine, 205 Vicks VapoRub, 216, 217 griseofulvin, 205 hyphae and spores, 108–109 naftifine, 205 immunohistochemistry, 128–129 terbinafine, 205, 210 interdigital tinea pedis, 166 antimycotics, 205, 206 KOH examination, 132 arthroconidia, 7 laser therapy, 193–195 biopsy, 108 medical devices, 200 biotin, 200 mild inflammation and fissuring, 165 Candida (see Candida) molecular techniques, 110 causes, 4 non-dermatophytic molds clinical assessment, 200 causes and prevalence, 61–62 clinical subtypes deep white superficial onychomycosis, DLSO, 133 64 fungal melanonychia, 134 diagnosis, 67–68 SPO, 134 DLSO, 64–66 SWO, 133–134 epidemiology, 62, 63 TDO, 134 pigmented onychomycosis, 65–67 clinical suspicion, 4 PSO, 64 cosmesis, 200 treatment, 62, 68 culture noninvasive diagnostic tool Candida spp., 106–107 (see Dermoscopy) Scopulariopsis brevicaulis, 108, 109 Nuvail, 200 Trichophyton rubrum, 108 optical coherence tomography, 128–129 dermatophyte process, 8 oral antifungals, 220 dermatophytoma, 106 pathogens, 4 in diabetics (see Diabetics) patterns of, 5 diagnosis, 114–117, 132 DLSO, 6 diffusion treatments, 206–207 EO, 7 DLSO (see Distal lateral subungual PSO, 7 onychomycosis (DLSO)) SO, 6–7 DNA-based rapid diagnostic techniques, TDO, 7, 8 129 phase-contrast hard X-ray microscopy, EO (see Endonyx onychomycosis (EO)) 128–129 epidemiology, 132–133 pigmented onychomycosis (see Pigmented examination, 105, 106 onychomycosis) Index 227 predisposing factors Paronychia, 76, 77 causes, 11–12 PAS stain. See Periodic acid-Schiff (PAS) stain genetic and non-modifiable risk factors, PCR. See Polymerase chain reaction (PCR) 12–13 Pediatric onychomycosis medical factors, 13–16 chemical avulsion, 178–179 physical and environmental factors, 16 distal lateral subungual type, 176 prevalence of, 4 genetic predisposition, 175 procedures laser therapy, 179 abrasion therapy, 192 melanocytic lesion, 176 carbon dioxide lasers, 193 photodynamic therapy, 179 "cold-steel" procedures, 193 prevalence, 175–176 concomitant oral or topical antifungal surgical avulsion, 178 therapy, 192 systemic antifungals, 177–178 iontophoresis/ultrasound, 193 topical antifungals, 178 negative galvanic current, 193 treatment, 176 occlusive urea, 193 Periodic acid-Schiff (PAS) stain radio-wave electrical energy, 193 EO, 58 prognostic factors histopathological role, 124 comorbid conditions, 162 PSO, 53 disease severity, 161 Peripheral arterial disease, 16 genetic mutations, 162 Periungual warts, 144–145 immunosuppression, 162 Phaeoid agents, 87 patient’s health status, 162 Photodynamic therapy (PDT), 68, 195 treatment failure, 162 Pigmented onychomycosis PSO (see Proximal subungual biological features, 88–89 onychomycosis
Load more

Recommended publications
  • Discovery of Anti-Amoebic Inhibitors from Screening the MMV Pandemic Response Box on Balamuthia Mandrillaris, Naegleria Fowleri
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.14.096776; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Article 2 Discovery of anti-amoebic inhibitors from screening 3 the MMV Pandemic Response Box on Balamuthia 4 mandrillaris, Naegleria fowleri and Acanthamoeba 5 castellanii 6 Christopher A. Rice1,2,Δ,†,*, Emma V. Troth2,3,†, A. Cassiopeia Russell2,3,†, and Dennis E. Kyle1,2,3,* 7 1 Department of Cellular Biology, University of Georgia, Athens, Georgia, USA. 8 2 Center for Tropical and Emerging Global Diseases, Athens, Georgia, USA. 9 3 Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA. 10 Δ Current address: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, 11 University of Georgia, Athens, Georgia, USA. 12 † These authors contributed equally to this work. 13 14 *Author correspondence: [email protected] (D.E.K) and [email protected] (C.A.R) 15 Received: date; Accepted: date; Published: date 16 Abstract: Pathogenic free-living amoebae, Balamuthia mandrillaris, Naegleria fowleri and several 17 Acanthamoeba species are the etiological agents of severe brain diseases, with case mortality rates 18 >90%. A number of constraints including misdiagnosis and partially effective treatments lead to 19 these high fatality rates. The unmet medical need is for rapidly acting, highly potent new drugs to 20 reduce these alarming mortality rates. Herein, we report the discovery of new drugs as potential 21 anti-amoebic agents.
    [Show full text]
  • (Schizotrypanum) Cruzi in Dog Hosts Paulo Marcos Da Matta Guedes,1 Julio A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2004, p. 4286–4292 Vol. 48, No. 11 0066-4804/04/$08.00ϩ0 DOI: 10.1128/AAC.48.11.4286–4292.2004 Copyright © 2004, American Society for Microbiology. All Rights Reserved. Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts Paulo Marcos da Matta Guedes,1 Julio A. Urbina,2 Marta de Lana,3 Luis C. C. Afonso,1 Vanja M. Veloso,1 Washington L. Tafuri,1 George L. L. Machado-Coelho,4 Egler Chiari,5 and Maria Terezinha Bahia1* Departamento de Cieˆncias Biolo´gicas,1 Departamento de Ana´lises Clínicas,3 and Departamento de Farma´cia,4 Universidade Federal de Ouro Preto, Ouro Preto, and Departamento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte,5 Minas Gerais, Brazil, and Centro de Biofísica y Bioquímica, Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela2 Received 25 March 2004/Returned for modification 8 June 2004/Accepted 20 July 2004 Albaconazole is an experimental triazole derivative with potent and broad-spectrum antifungal activity and a remarkably long half-life in dogs, monkeys, and humans. In the present work, we investigated the in vivo activity of this compound against two strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas’ disease, using dogs as hosts. The T. cruzi strains used in the study were previously characterized (murine model) as susceptible (strain Berenice-78) and partially resistant (strain Y) to the drugs currently in clinical use, nifurtimox and benznidazole. Our results demonstrated that albaconazole is very effective in suppressing the proliferation of the parasite and preventing the death of infected animals.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
    United States International Trade Commission Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix USITC Publication 4208 December 2010 U.S. International Trade Commission COMMISSIONERS Deanna Tanner Okun, Chairman Irving A. Williamson, Vice Chairman Charlotte R. Lane Daniel R. Pearson Shara L. Aranoff Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix Publication 4208 December 2010 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 15, 2010, set forth at the end of this publication, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the United States International Trade Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement changes to the Pharmaceutical Appendix, effective on January 1, 2011. Table 1 International Nonproprietary Name (INN) products proposed for addition to the Pharmaceutical Appendix to the Harmonized Tariff Schedule INN CAS Number Abagovomab 792921-10-9 Aclidinium Bromide 320345-99-1 Aderbasib 791828-58-5 Adipiplon 840486-93-3 Adoprazine 222551-17-9 Afimoxifene 68392-35-8 Aflibercept 862111-32-8 Agatolimod
    [Show full text]
  • Integrated Molecular Profiling for Analyzing and Predicting Therapeutic Mechanism, Response, Biomarker and Target
    INTEGRATED MOLECULAR PROFILING FOR ANALYZING AND PREDICTING THERAPEUTIC MECHANISM, RESPONSE, BIOMARKER AND TARGET Jia Jia (B. Sci & M. Sci, Zhejiang University) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF PHARMACY NATIONAL UNIVERSITY OF SINGAPORE 2010 Acknowledgements ACKNOWLEDGEMENTS I would like to deeply thank Professor Chen Yu Zong, for his constant encouragement and advice during the entire period of my postgraduate studies. In particular, he has guided me to make my research applicable to the real world problem. This work would not have been possible without his kindness in supporting me to shape up the manuscript for publication. I am also tremendously benefited from his profound knowledge, expertise in scientific research, as well as his enormous support, which will inspire and motivate me to go further in my future professional career. I am also grateful to our BIDD group members for their insight suggestions and collaborations in my research work: Dr. Tang Zhiqun, Ms. Ma Xiaohua, Mr. Zhu Feng, Ms. Liu Xin, Ms. Shi Zhe, Dr. Cui Juan, Mr. Tu Weimin, Dr. Zhang Hailei, Dr. Lin Honghuang, Dr. Liu Xianghui, Dr. Pankaj Kumar, Dr Yap Chun wei, Ms. Wei Xiaona, Ms. Huang Lu, Mr. Zhang Jinxian, Mr. Han Bucong, Mr. Tao Lin, Dr. Wang Rong, Dr. Yan Kun. I thank them for their valuable support and encouragement in my work. Finally, I owe my gratitude to my parents for their forever love, constant support, understanding, encouragement and strength throughout my life. A special appreciation goes to all for love and support. Jia Jia August 2010 I Table of Contents TABLE OF CONTENTS 1.1 Overview of mechanism and strategies of molecular-targeted therapeutics ...................................
    [Show full text]
  • 1,4-Disubstituted-1,2,3-Triazole Compounds Induce Ultrastructural Alterations in Leishmania Amazonensis Promastigote
    International Journal of Molecular Sciences Article 1,4-Disubstituted-1,2,3-Triazole Compounds Induce Ultrastructural Alterations in Leishmania amazonensis Promastigote: An in Vitro Antileishmanial and in Silico Pharmacokinetic Study Fernando Almeida-Souza 1,2,* , Verônica Diniz da Silva 3,4, Gabriel Xavier Silva 5, Noemi Nosomi Taniwaki 6, Daiana de Jesus Hardoim 2, Camilla Djenne Buarque 3, 1, , 2, Ana Lucia Abreu-Silva * y and Kátia da Silva Calabrese y 1 Pós-graduação em Ciência Animal, Universidade Estadual do Maranhão, São Luís 65055-310, Brazil 2 Laboratório de Imunomodulação e Protozoologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil; [email protected] (D.d.J.H.); calabrese@ioc.fiocruz.br (K.d.S.C.) 3 Laboratório de Síntese Orgânica, Pontifícia Universidade Católica, Rio de Janeiro 22451-900, Brazil; [email protected] (V.D.d.S.); [email protected] (C.D.B.) 4 Faculdade de Ciência e Tecnologia, Universidade Nova de Lisboa, 2825-149 Caparica, Portugal 5 Rede Nordeste de Biotecnologia, Universidade Federal do Maranhão, São Luís 65080-805, Brazil; [email protected] 6 Núcleo de Microscopia Eletrônica, Instituto Adolfo Lutz, São Paulo 01246-000, Brazil; [email protected] * Correspondence: [email protected] (F.A.-S.); [email protected] (A.L.A.-S.) These authors equally contributed to this work. y Received: 26 June 2020; Accepted: 14 July 2020; Published: 18 September 2020 Abstract: The current standard treatment for leishmaniasis has remained the same for over 100 years, despite inducing several adverse effects and increasing cases of resistance. In this study we evaluated the in vitro antileishmanial activity of 1,4-disubstituted-1,2,3 triazole compounds and carried out in silico predictive study of their pharmacokinetic and toxicity properties.
    [Show full text]
  • Review Article Sporotrichosis: an Overview and Therapeutic Options
    Hindawi Publishing Corporation Dermatology Research and Practice Volume 2014, Article ID 272376, 13 pages http://dx.doi.org/10.1155/2014/272376 Review Article Sporotrichosis: An Overview and Therapeutic Options Vikram K. Mahajan Department of Dermatology, Venereology & Leprosy, Dr. R. P. Govt. Medical College, Kangra, Tanda, Himachal Pradesh 176001, India Correspondence should be addressed to Vikram K. Mahajan; [email protected] Received 30 July 2014; Accepted 12 December 2014; Published 29 December 2014 Academic Editor: Craig G. Burkhart Copyright © 2014 Vikram K. Mahajan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sporotrichosis is a chronic granulomatous mycotic infection caused by Sporothrix schenckii, a common saprophyte of soil, decaying wood, hay, and sphagnum moss, that is endemic in tropical/subtropical areas. The recent phylogenetic studies have delineated the geographic distribution of multiple distinct Sporothrix species causing sporotrichosis. It characteristically involves the skin and subcutaneous tissue following traumatic inoculation of the pathogen. After a variable incubation period, progressively enlarging papulo-nodule at the inoculation site develops that may ulcerate (fixed cutaneous sporotrichosis) or multiple nodules appear proximally along lymphatics (lymphocutaneous sporotrichosis). Osteoarticular sporotrichosis or primary pulmonary sporotrichosis are rare and occur from direct inoculation or inhalation of conidia, respectively. Disseminated cutaneous sporotrichosis or involvement of multiple visceral organs, particularly the central nervous system, occurs most commonly in persons with immunosuppression. Saturated solution of potassium iodide remains a first line treatment choice for uncomplicated cutaneous sporotrichosis in resource poor countries but itraconazole is currently used/recommended for the treatment of all forms of sporotrichosis.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • 2011/058582 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date i 1 m 19 May 2011 (19.05.2011) 2011/058582 Al (51) International Patent Classification: Road, Sholinganallur, Chennai 600 119 (IN). CHEN- C07C 259/06 (2006.01) A61P 31/00 (2006.01) NIAPPAN, Vinoth Kumar [IN/IN]; Orchid Research C07D 277/46 (2006.01) A61K 31/426 (2006.01) Laboratories Ltd., R & D Centre: Plot No: 476/14, Old C07D 277/48 (2006.01) A61K 31/55 (2006.01) Mahabalipuram Road, Sholinganallur, Chennai 600 119 C07D 487/08 (2006.01) (IN). GANESAN, Karthikeyan [IN/IN]; Orchid Re search Laboratories Ltd., R & D Centre: Plot No: 476/14, (21) International Application Number: Old Mahabalipuram Road, Sholinganallur, Chennai 600 PCT/IN20 10/000738 119 (IN). NARAYANAN, Shridhar [IN/IN]; Orchid Re (22) International Filing Date: search Laboratories Ltd., R & D Centre: Plot No: 476/14, 12 November 2010 (12.1 1.2010) Old Mahabalipuram Road, Sholinganallur, Chennai 600 119 (IN). (25) Filing Language: English (74) Agent: UDAYAMPALAYAM PALANISAMY, (26) Publication Language: English Senthilkumar; Orchid Chemicals & Pharmaceuticals (30) Priority Data: LTD., R & D Centre: Plot No: 476/14, Old Mahabalipu 2810/CHE/2009 16 November 2009 (16. 11.2009) IN ram Road, Sholinganallur, Chennai 600 119 (IN). (71) Applicant (for all designated States except US): OR¬ (81) Designated States (unless otherwise indicated, for every CHID RESEARCH LABORATORIES LTD. [IN/IN]; kind of national protection available): AE, AG, AL, AM, Orchid Towers, 313, Valluvar Kottam High Road, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, Nungambakkam, Chennai 600 034 (IN).
    [Show full text]
  • WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/195872 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (74) Agents: CHOTIA, Meenakshi et al; K&S Partners | Intel A 25/12 (2006.01) A61K 8/11 (2006.01) lectual Property Attorneys, 4121/B, 6th Cross, 19A Main, A 25/34 (2006.01) A61K 8/49 (2006.01) HAL II Stage (Extension), Bangalore 560038 (IN). A01N 37/06 (2006.01) A61Q 5/00 (2006.01) (81) Designated States (unless otherwise indicated, for every A O 43/12 (2006.01) A61K 31/44 (2006.01) kind of national protection available): AE, AG, AL, AM, AO 43/40 (2006.01) A61Q 19/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A01N 57/12 (2006.01) A61K 9/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, AOm 59/16 (2006.01) A61K 31/496 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB20 14/06 1925 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 June 2014 (03.06.2014) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • A Ketoconazole Susceptibility Test for Malassezia Pachydermatis Using Modified Leeming–Notman Agar
    Journal of Fungi Article A Ketoconazole Susceptibility Test for Malassezia pachydermatis Using Modified Leeming–Notman Agar Bo-Young Hsieh 1,2, Wei-Hsun Chao 3, Yi-Jing Xue 2 and Jyh-Mirn Lai 2,* 1 Lugu Township Administration, Nanto County 55844, Taiwan; [email protected] 2 College of Veterinary Medicine, National Chiayi University, No. 580, XinMin Rd., Chiayi City 60054, Taiwan; [email protected] 3 Department of Hospitality Management, WuFung University, Chiayi City 60054, Taiwan; [email protected] * Correspondence: [email protected]; Tel.: +886-5-2732920; Fax: +886-5-2732917 Received: 18 September 2018; Accepted: 14 November 2018; Published: 16 November 2018 Abstract: The aim of this study was to establish a ketoconazole susceptibility test for Malassezia pachydermatis using modified Leeming–Notman agar (mLNA). The susceptibilities of 33 M. pachydermatis isolates obtained by modified CLSI M27-A3 method were compared with the results by disk diffusion method, which used different concentrations of ketoconazole on 6 mm diameter paper disks. Results showed that 93.9% (31/33) of the minimum inhibitory concentration (MIC) values obtained from both methods were similar (consistent with two methods within 2 dilutions). M. pachydermatis BCRC 21676 and Candida parapsilosis ATCC 22019 were used to verify the results obtained from the disk diffusion and modified CLSI M27-A3 tests, and they were found to be consistent. Therefore, the current study concludes that this new novel test—using different concentrations of reagents on cartridge disks to detect MIC values against ketoconazole—can be a cost-effective, time-efficient, and less technically demanding alternative to existing methods.
    [Show full text]
  • WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/134796 Al 11 September 2015 (11.09.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/14 (2006.01) A61K 47/10 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 9/16 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/0 19042 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 5 March 2015 (05.03.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/948,173 5 March 2014 (05.03.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 14/307,138 17 June 2014 (17.06.2014) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: PROFESSIONAL COMPOUNDING CEN¬ LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TERS OF AMERICA [US/US]; 9901 South Wilcrest SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Drive, Houston, TX 77099 (US).
    [Show full text]
  • WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/102407 Al 07 June 2018 (07.06.2018) W !P O PCT (51) International Patent Classification: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, C07K 7/60 (2006.01) G01N 33/53 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CI2Q 1/18 (2006.01) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (21) International Application Number: KM, ML, MR, NE, SN, TD, TG). PCT/US2017/063696 (22) International Filing Date: Published: 29 November 201 7 (29. 11.201 7) — with international search report (Art. 21(3)) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/427,507 29 November 2016 (29. 11.2016) US 62/484,696 12 April 2017 (12.04.2017) US 62/53 1,767 12 July 2017 (12.07.2017) US 62/541,474 04 August 2017 (04.08.2017) US 62/566,947 02 October 2017 (02.10.2017) US 62/578,877 30 October 2017 (30.10.2017) US (71) Applicant: CIDARA THERAPEUTICS, INC [US/US]; 63 10 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (US). (72) Inventors: BARTIZAL, Kenneth; 7520 Draper Avenue, Unit 5, La Jolla, CA 92037 (US). DARUWALA, Paul; 1141 Luneta Drive, Del Mar, CA 92014 (US). FORREST, Kevin; 13864 Boquita Drive, Del Mar, CA 92014 (US).
    [Show full text]